Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study is a research paper published in Cardiovascular Drugs and Therapy (2022). On theSindex it has a DataRank of 0.240. It has been cited 3 times, with 2 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.208
From this paper's citation signal
Citation Network Contribution
0.0317
From 2 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 2 citers.
National Heart, Lung, and Blood Institute
Grant: U01HL128606
National Heart, Lung, and Blood Institute
Grant: U01HL128626
National Institutes of Health
Grant: 5U01HL128626-02
Clinical Implementation of Clopidogrel Pharmacogenetics: The TAILOR-PCI Trial - DCC
National Institutes of Health
Grant: 5U01HL128606-03
Clinical Implementation of Clopidogrel Pharmacogenetics: The TAILOR-PCI Trial - CCC - Lead Application
FWCI
0.46
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals